Related Experiment Video
Updated: Jun 2, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models
Teppei Matsuo1, Satoshi S Nishizuka, Kazushige Ishida
1Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka 020-8505, Iwate Japan. snishizu@iwate-med.ac.jp.
Background:
The binding of EGFR and its ligands leads to autophosphorylation of receptor tyrosine kinase as well as subsequent activation of signal transduction pathways that are involved in regulating cellular proliferation, differentiation, and survival. An EGFR inhibitor, cetuximab binds to EGFR and consequently blocks a variety of cellular processes. KRAS/BRAF mutations are known to be associated with a low response rate to cetuximab. In the present study, to clarify the anti-tumor mechanisms of cetuximab, we evaluated the KRAS/BRAF status, phosphorylation level of the EGFR pathway, and the tumor suppression effect in vivo, using a human colon cancer cell line HT29, which exhibited the highest EGFR expression in response to the cetuximab therapy among the 6 colorectal cancer cell lines tested.
Findings:
The conventional growth suppression assay did not work efficiently with cetuximab. EGF, TGF-α, and IGF activated the EGFR/MAPK cell signaling pathway by initiating the phosphorylation of EGFR. Cetuximab partially inhibited the EGFR/MAPK pathway induced by EGF, TGF-α, and IGF. However, cetuximab exposure induced the EGFR, MEK, and ERK1/2 phosphorylation by itself. Mouse xenograft tumor growth was significantly inhibited by cetuximab and both cetuximab-treated and -untreated xenograft specimens exhibited phosphorylations of the EGFR pathway proteins.
Conclusions:
We have confirmed that cetuximab inhibited the EGFR/MAPK pathway and reduced tumor growth in the xenografts while the remaining tumor showed EGFR pathway activation. These results suggest that: ( i ) The effect of cetuximab in growth signaling is not sufficient to induce complete growth suppression in vitro; ( ii ) time-course monitoring may be necessary to evaluate the effect of cetuximab because EGFR signaling is transmitted in a minute order; and ( iii ) cetuximab treatment may have cells acquired resistant selectively survived in the heterogeneous cancer population.
Insights
Cetuximab partially inhibits the epidermal growth factor receptor (EGFR) pathway in colon cancer, reducing tumor growth but not causing complete suppression. Further studies are needed to understand resistance mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Epidermal growth factor receptor (EGFR) signaling regulates cell proliferation, differentiation, and survival.
- Cetuximab, an EGFR inhibitor, blocks cellular processes but shows limited efficacy in KRAS/BRAF-mutated cancers.
- HT29 human colon cancer cells exhibit high EGFR expression, making them a relevant model for cetuximab studies.
Purpose of the Study:
- To elucidate the anti-tumor mechanisms of cetuximab in colon cancer.
- To evaluate the impact of cetuximab on EGFR pathway phosphorylation and tumor suppression in vivo.
- To assess the role of KRAS/BRAF status in cetuximab response.
Main Methods:
- Assessed cetuximab's effect on EGFR/MAPK pathway phosphorylation induced by EGF, TGF-α, and IGF.
- Evaluated cetuximab's impact on EGFR, MEK, and ERK1/2 phosphorylation.
- Utilized mouse xenograft models to assess cetuximab's tumor suppression effect in vivo.
Main Results:
- Cetuximab partially inhibited the EGFR/MAPK pathway but induced EGFR pathway phosphorylation independently.
- Mouse xenograft tumor growth was significantly inhibited by cetuximab.
- EGFR pathway proteins remained phosphorylated in both cetuximab-treated and untreated xenograft specimens.
Conclusions:
- Cetuximab inhibits the EGFR/MAPK pathway and reduces tumor growth, but complete in vitro growth suppression was not achieved.
- Time-course monitoring is crucial for evaluating cetuximab's effects due to the rapid nature of EGFR signaling.
- Cetuximab treatment may lead to the selective survival of resistant cells within heterogeneous tumors.
